In compliance with current regulations, let us know which audience you belong to:
Effective from January 1st, after over 40 years of dedicated work to create and develop Espansione Group’s ecosystem of technologies and solutions, alongside our global presence, Rodolfo Pomar and Morena Gomedi, the company’s founders, will retire from their day to day operative roles.
The company’s vision will be carried out in continuity by the management team that joined the company last year and has been working on an ambitious business plan ever since. The new leadership, who has entered the company’s capital through the acquisition of a majority stake in November 2021, will see Alessandro Fier stepping up as CEO and President, Luca Trimigno as Chief Strategy & Corporate Development Officer, and Matteo Corbellino as Chief Marketing and Innovation Officer. Mr. Fier, Mr. Trimigno and Mr. Corbellino will all preserve their roles within the Board of Directors as Executive Members.
Mr. Pomar will step down from his roles of President and CEO, while Mrs. Gomedi will step down from her role of Head of Scientific Management. They will maintain a place on the company’s Board of Directors as Non-executive Members, to provide continuity. Mr. Pomar and Mrs. Gomedi will also preserve a minority stake in the company.
Espansione Group is today at its highest point when it comes to both reach, resonance, and adoption of its technologies. With a unique pipeline of product innovations and renewed ambitions for global leadership in the dry eye market and beyond, the new leadership is looking forward to carrying out its long-term ambition, with increased investments in all company areas and strengthened ties with its partners.
The year that just started will see the Group getting closer to its partners worldwide, with renewed trust and a solid congress presence in all continents, establishing new paradigms in ophthalmology and beyond.
About Espansione Group
Espansione Group is a pioneer in the medtech industry, on a mission to develop and market innovative, non-invasive solutions for prevention and management of conditions in ophthalmology and beyond.
The company’s certified medical solutions leverage proprietary technologies such as Light Modulation™ Low-level Light Therapy (LM™ LLLT) photobiomodulation (PBM), with an ambition to redefine standards of care by expanding on their applications, with a constant commitment to science, research and development, and customer excellence.
Strategic partnerships with the industry, a strong commitment to scientific excellence and a will to shape the future have enabled Espansione Group’s advanced medical technologies to be present in over 50 countries, serving thousands healthcare providers worldwide.
For more information, visit www.espansionegroup.it
Espansione Group Press Office
press@espansione.it
© 2023 Espansione Group, All Rights Reserved
Posted on February 1st, 2023 in Newsroom